Trials / Completed
CompletedNCT06392763
Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 602 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor (CAR) T cells (CART-cells) (KYMRIAH or YESCARTA): paediatric and young adult patients (up to and including 25 years of age) with acute lymphoblastic leukaemia (ALL); and adult patients (18 years of age or older) with DLBCL.
Conditions
Timeline
- Start date
- 2021-08-03
- Primary completion
- 2023-04-28
- Completion
- 2023-04-28
- First posted
- 2024-04-30
- Last updated
- 2024-04-30
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06392763. Inclusion in this directory is not an endorsement.